A 295
Alternative Names: A-295Latest Information Update: 26 Feb 2024
At a glance
- Originator Klus Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Adenosine A2A receptor antagonists; Adenosine A2B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 19 Jan 2024 A 295 is available for licensing as of 19 Jan 2024. https://www.kluspharma.com/contact
- 19 Jan 2024 Preclinical trials in Cancer in USA (Unspecified) (Klus Pharma pipeline, January 2024)